PolarityBio转发了
We are excited to announce the closing of our financing to push forward our Phase III trial! https://lnkd.in/eSv4tMMF
关于我们
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE?. PolarityTE has an open investigational new drug application (IND) for SkinTE? with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE? needed to support a biologics license application (BLA) for a chronic cutaneous ulcer indication. SkinTE? is available for investigational use only. Learn more at www.PolarityTE.com.
- 网站
-
https://www.polarityte.com/
PolarityBio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Salt Lake City，Utah
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
获取路线
1960 S 4250 W
US，Utah，Salt Lake City，84104
PolarityBio员工
动态
-
We are excited to announce the closing of our financing to push forward our Phase III trial! https://lnkd.in/eSv4tMMF
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
finance.yahoo.com
-
We are grateful for the patients, investigators, and hardworking PolarityTE team that has made the COVER DFUS II Trial possible! John Stetson Ned Swanson, MD Marytheresa Ifediba David Armstrong PERI Dr Marissa Carter #diabeticfoot #celltherapy #regenerativemedicine #clinicaltrials
We are excited to announce first subject screened in our Phase III Pivotal Study Evaluating Investigational New Drug SkinTE? in Diabetic Foot Ulcers! https://lnkd.in/eQGXcYg8
PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE? in Diabetic Foot Ulcers
globenewswire.com
-
We are excited to announce first subject screened in our Phase III Pivotal Study Evaluating Investigational New Drug SkinTE? in Diabetic Foot Ulcers! https://lnkd.in/eQGXcYg8
PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE? in Diabetic Foot Ulcers
globenewswire.com
-
PolarityBio转发了
Final analysis of our randomized controlled trial comparing #SkinTE to standard of care in the treatment of #DFUs published in International Wound Journal. Couldn't be more proud of the PolarityTE and PERI teams for this study that demonstrated SkinTE closed >2x more diabetic foot ulcers within 12 weeks than standard of care. A huge congratulations to Ashlee Fishleigh, Nikolai Sopko, MD, PhD, Charles Zelen, DPM, David Armstrong, Dennis Orgill, MD, PhD, Robert D. Galliano, MD, Paul M. Glat, MD, Felix Sigal, DPM, Lawrence DiDomenico, DPM, Rob Snyder, DPM, MSc, MBA, CWSP, FFPM RCPS(Glasg), and Dr Marissa Carter. #AHSC #autologous #autologousheterogeneousskinconstruct #wounds #diabeticfootulcers #DFU
A multicenter, randomized controlled clinical trial evaluating the effects of a novel autologous heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Final analysis
onlinelibrary.wiley.com